What is Alnylam Pharmaceuticals's revenue?

Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.

Is Alnylam Pharmaceuticals profitable?

Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.

What are Alnylam Pharmaceuticals's profit margins?

Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.

What is Alnylam Pharmaceuticals's earnings per share?

Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.

Where does Alnylam Pharmaceuticals's income statement data come from?

Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Alnylam Pharmaceuticals ALNY Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Total revenue	$1.17B+6.4%	$1.1B-12.2%	$1.25B+61.4%	$773.69M+30.2%	$594.19M+0.2%
Total cost of revenue	$207.52M-22.5%	$267.72M+35.7%	$197.23M+38.9%	$142.03M+102%	$70.18M-31.6%
Gross profit	$959.66M+15.7%	$829.31M-21.2%	$1.05B+66.5%	$631.66M+20.5%	$524.01M+6.8%
Gross margin	82.2%+6.6pp	75.6%-8.6pp	84.2%+2.6pp	81.6%-6.5pp	88.2%+5.5pp
Research and development	$364.87M-2.0%	$372.22M+3.7%	$358.81M+10.9%	$323.62M+22.1%	$265.12M-11.7%
Selling, general and administrative	$322.55M-0.9%	$325.37M+1.0%	$322.08M-0.4%	$323.31M+34.7%	$239.95M-18.8%
Total costs & expenses	$898.54M-6.9%	$965.32M+9.6%	$881.04M+11.5%	$789.89M+37.1%	$576.11M-17.5%
Operating income	$268.64M+104%	$131.72M-64.2%	$367.98M+2,372%	-$16.2M-190%	$18.08M+117%
Operating margin	23%+11.0pp	12%-17.5pp	29.5%+31.6pp	-2.1%-5.1pp	3%+20.8pp
Interest expense	$69.29M+5.9%	$65.4M+47.3%	$44.4M+10.3%	$40.25M-31.0%	$58.31M+49.6%
Other income (expense), net	-$46.98M-3.4%	-$45.46M+64.8%	-$129.01M-573%	-$19.16M+6.3%	-$20.45M+77.0%
Income before income taxes	$221.65M+157%	$86.26M-63.9%	$238.97M+776%	-$35.36M-1,393%	-$2.37M+98.8%
Income tax expense	$15.66M—	——	-$12.12M-139%	$30.92M+94.7%	$15.88M+114%
Net income	$205.99M+84.7%	$111.54M-55.6%	$251.08M+479%	-$66.28M-263%	-$18.25M+78.2%
Net margin	17.6%+7.5pp	10.2%-9.9pp	20.1%+28.7pp	-8.6%-5.5pp	-3.1%+11.0pp
Diluted earnings per share	$1.51+84.1%	$0.82-55.4%	$1.84+461%	-$0.51-264%	-$0.14+78.5%
EBITDA	$282.19M+94.3%	$145.22M-62.0%	$381.79M+17,031%	-$2.26M-107%	$32.48M+136%
EBITDA margin	24.2%+10.9pp	13.2%-17.3pp	30.6%+30.9pp	-0.3%-5.8pp	5.5%+20.8pp
EBIT	$268.64M+104%	$131.72M-64.2%	$367.98M+2,372%	-$16.2M-190%	$18.08M+117%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Alnylam Pharmaceuticals.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alnylam Pharmaceuticals's revenue?: Alnylam Pharmaceuticals (ALNY) generated $4.3B in revenue over the trailing twelve months, up 82.6% year over year.
Is Alnylam Pharmaceuticals profitable?: Alnylam Pharmaceuticals reported $502.3M in net income over the trailing twelve months, a 11.7% net margin.
What are Alnylam Pharmaceuticals's profit margins?: Gross margin is 81.0% and operating margin is 17.5%, with a 11.7% net margin.
What is Alnylam Pharmaceuticals's earnings per share?: Alnylam Pharmaceuticals's diluted EPS over the trailing twelve months is $3.66.
Where does Alnylam Pharmaceuticals's income statement data come from?: Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.